ImmunityBio (IBRX) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: adult, advocated, aggressively, backbone, Becerra, BGC, bifurcated, bifurcation, biomedical, blinded, bolster, boosted, branch, Canada, Carlo, Catalyst, Chevron, Cir, citing, cohort, colorectal, compliant, compound, Connecticut, constantly, count, CR, cumulative, destroyed, dispersed, doctrine, DOR, double, earliest, eighteen, enumerated, expert, foreclosure, Gaza, GBM, Hong, iBCG, IIb, Indiana, Infinity, introduced, Iowa, IPRT, IRA, Kong, Korean, longstanding, mechanism, median, Merck, misuse, Montana, Monte, NantXL, navigate, NSCLC, Oberland, offense, Oregon, papillary, path, percent, phishing, play, pool, pretax, QMSR, QUILT, reconciliation, reconciling, reconsideration, repayment, Republic, retaliation, retrospective, RIPA, SA, sBCG, science, segment, segmentation, sharply, shipment, shortage, SII, Smart, SPOA, stimulation, subordinated, subordination, Tennessee, ThAnktiva, therewith, thirty, threshold, Tranche, triangle, turnover, twelfth, tying, unconstitutional, uncured, undermine, underway, unique, upper, uptake, Urological, Utah, Washington, Yemen

Removed: AB, abetting, Adam, admission, aiding, allocable, answered, antiretroviral, appraisal, Assembly, Barbara, barring, bear, binomial, bore, borrower, Boyden, CAMT, Chancery, clarify, Clayland, close, complicating, compute, computer, confirmed, Conkwest, contemplated, conveniently, copy, cure, cybersecurity, Cynviloq, cytokine, DAMP, deducting, denied, deployment, designing, Diego, dismissed, dissemination, dissenting, distancing, Dyad, earned, entirety, exhaustive, fault, fluidity, fractional, globally, Gordon, Gray, great, heighten, Henderson, home, identifiable, incorporated, inducer, infected, joined, Keytruda, Kingdom, lattice, logo, lymphocyte, main, metastatic, mitigation, oral, origination, pancreatic, participant, personally, petition, prediction, preempted, prejudgment, preliminarily, premarket, prioritization, purport, purported, regular, reopened, responded, San, satisfactory, Seller, sequester, Stipulation, stored, strive, Sturm, Ta, text, theory, trustee, unprecedented, upcoming, virally, Waldman, weather, wrongful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IBRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Richard Adcock, the Chief Executive Officer of ImmunityBio, Inc. (the “Company”), hereby certify, that, to my knowledge:

i.the Quarterly Report of the Company on Form 10-Q for the quarter ended March 31, 2024 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

ii.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2024	By:	/s/ Richard Adcock
		Richard Adcock
		Chief Executive Officer and President
		(Principal Executive Officer)